Skip to main content
OpenTrials
Completed

NCT Number: NCT02815943

Postprandial Metabolism After Bariatric Surgery in Type 2 Diabetes

Bariatric surgery procedures have now been firmly demonstrated to lead to significant improvement and even, in many cases, complete reversal of abnormal glucose homeostasis in type 2 diabetes (T2D). Various surgery procedures are can be performed to induce weight loss. The most striking anti-diabetic effects are observed with biliopancreatic diversion with duodenal switch (BPD-DS), followed by Roux-in-Y gastric bypass (RYGB) and sleeve gastrectomy (SG). The first two procedures induce both a restriction of energy intake and a low absorption of dietary fatty acids while the latter exclusively targets energy intake restriction. The investigator and others have shown that improvement of T2D occurs within days after BPD-DS or RYGB in the vast majority of patients, prior to any significant weight loss. This very rapid metabolic recovery is explained by a normalization of β-cell function after meal challenges and ameliorated hepatic insulin sensitivity. The investigator and others have shown that these acute anti-diabetic effects are mostly recapitulated by matched caloric restriction, independent of changes in gastrointestinal hormones, showing the importance of gastrointestinal-derived energy fluxes for acute diabetes control. Muscle insulin sensitivity, on the other hand, improves more slowly in association with weight loss, demonstrating the heterogeneous metabolic response of the various organs to BPD-DS. Some preliminary studies also demonstrate a rapid reduction of NEFA levels and production rate upon i.v. administration of lipids during euglycemic hyperinsulinemic clamps. This very rapid improvement in NEFA tolerance strongly suggests that adipose tissue storage of circulating fatty acids also improves very rapidly, prior to any significant weight loss, after BPD-DS. It may also suggest an acceleration of oxidative fatty acid metabolism in organs such as the liver, the heart and/or skeletal muscles. Studies of the rapid metabolic changes after bariatric surgery conducted thus far rapidly improved the understanding of the fundamental pathogenic defects of T2D. However, much remains to be understood about the acute changes in gastrointestinal-derived metabolic fluxes, organ-specific metabolic responses to bariatric surgery and their relationship with the reversal of T2D. Using in vivo methodological approaches, the investigator proposes to investigate the early organ-specific changes in dietary fatty acid metabolism in response to BPD-DS vs. SG and their relation to improved systemic changes in glucose homeostasis, insulin sensitivity and β-cell function in patients with T2D.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centre de recherche du CHUS

Sherbrooke, Quebec, J1H 5N4, Canada

About this study

Participants will undergo a metabolic study before and 8 to 12 days after bariatric surgery after a 12-hour fast and a three-day food and physical activity diary with accelerometry. The patients recover very rapidly from the surgery and will be able to participate to the proposed investigations the week after their hospitalization on an outpatient basis on the earliest week day between 8 and 12 days after the surgery procedure. The metabolic study is a 6-hour meal test using Positron Emitting Tomography (PET).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Four groups of 11 subjects each: obese subjects with T2D or with normal glucose tolerance undergoing either BPD-DS or SG for treatment of obesity. T2D and control subjects will be matched for age (± 3 years), BMI (± 2 kg/m2) and gender across both BPD-DS and SG.

Exclusion criteria

  • presence of overt cardiovascular disease, as assessed by history, physical exam, and abnormal EKG;
  • treatment with a fibrate, a thiazolidinedione, a beta-blocker or other drugs known to affect lipid or carbohydrate metabolism (except statins, sulfonylurea, metformin, and other antihypertensive agents that can be temporarily stopped prior to the protocols);
  • presence of liver or renal disease, uncontrolled thyroid disorder or other major illnesses;
  • smoking (>1 cigarette/day) and/or consumption of more than 2 alcoholic beverages per day;
  • prior history or current fasting plasma cholesterol level > 7 mmol/l or fasting TG > 6 mmol/l;
  • any other contraindication to temporarily stop current medications for hyperglycemia, lipids, or hypertension.

Treatment and study plan

biliopancreatic diversion with duodenal switch

Procedure

Sleeve gastrectomy

Procedure

liquid meal

Other

will be consumed over 30 minutes with [U-13C]-palmitate (0.2 g mixed in the liquid meal) and H2-glucose

PET/scan

Radiation

a dynamic and whole body PET acquisition will be performed on a thoraco-abdominal segment, 150 minutes after an oral administration of 18FTHA

[7,7,8,8-2H]-palmitate

Other

i.v. administration of [7,7,8,8-2H]-palmitate (in 25% human albumin) from time -60 to 360 min.

Indirect calorimetry

Device

will be performed every hour throughout the protocol along with exhaled breath collection

Primary outcomes

  1. glucose metabolism

    Time frame: 2 years

    will be determined using tracers of glucose

  2. dietary fatty acid uptake

    Time frame: 2 years

    assessed using PET/CT method with oral administration of 18FTHA

  3. whole body inter-organ partitioning

    Time frame: 2 years

    assessed using PET/CT method with oral administration of 18FTHA

  4. lipid metabolism

    Time frame: 2 years

    will be determined using tracers of fatty acids

Secondary outcomes

  1. Dietary fatty acid oxidation rate

    Time frame: 2 years

    will be measured using breath 13CO2 enrichment

  2. Total oxidation rate

    Time frame: 2 years

    will be determined by indirect calorimetry

  3. Hormonal responses

    Time frame: 2 years

    will be determined using a multiplex assay system.

  4. Insulin sensitivity

    Time frame: 2 years

    will be determined using different standard methods, including the HOMA-IR

  5. Insulin secretion index (ISI)

    Time frame: 2 years

    will be assessed using deconvolution of plasma C-peptide with standard C-peptide kinetic parameters

  6. habitual food intake

    Time frame: 2 years

    with a 3-day food record,

  7. physical activity

    Time frame: 2 years

    with portable arm band accelerometry for 3 days prior to each metabolic study

Sponsors and collaborators

Lead sponsor

Université de Sherbrooke

Other

Collaborators

  • Laval University

Registry information

Acronym: CB4

Important dates

Study start
2015
Primary completion
2019
Study completion
2019
First posted
Jun 28, 2016
Registry last updated
May 17, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.